# OnCo record paper-keynote-189-nejm-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-189-nejm-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-189-nejm-2018" ;
  schema:name "KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation"@en ;
  schema:description "Adding pembrolizumab to standard chemotherapy roughly halved the risk of death in newly diagnosed non-squamous lung cancer, whatever the PD-L1 level, making chemo-immunotherapy the default first treatment."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-189-nejm-2018/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1801005>, <https://clinicaltrials.gov/study/NCT02578680> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1801005> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/first-line/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/irae/> ;
  onco:people <https://onco.cc/people/enriqueta-felip/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .